Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial

Date
2018
Author
Ikeda, Hiroko
Pelov, Diana
Ridolfi, Antonia
Fan, Jenna
Dlugos, Dennis J.
de Vries, Petrus J.
Nabbout, Rima
Curatolo, Paolo
Franz, David N.
Lawson, John A.
Polster, Tilman
Yapici, Zuhal
French, Jacqueline A.
Voi, Maurizio
Metadata
Show full item record
Abstract
Background Epilepsy occurs in 70-90% of patients with tuberous sclerosis complex. We aimed to assess the efficacy and safety of adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex in paediatric patients enrolled in the EXIST-3 trial, a double-blind, placebo-controlled, randomised, phase 3 study.
URI
http://hdl.handle.net/20.500.12627/70820
https://doi.org/10.1016/s2352-4642(18)30099-3
Collections